Kalaris Therapeutics Statistics
Want to see KLRS full AI Analyst Report?
Kalaris Therapeutics (KLRS) Stock Statistics & Valuation Metrics
Total Valuation
Kalaris Therapeutics has a market cap or net worth of $52.85M. The enterprise value is $4.72M.
- Market Cap
- $52.85M
- Enterprise Value
- $4.72M
Share Statistics
Kalaris Therapeutics has 23,804,981 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,804,981
- Owned by Insiders
- 54.44%
- Owned by Institutions
- 7.49%
Financial Efficiency
Kalaris Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -41.08%.
- Return on Equity (ROE)
- -0.55
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -41.08%
- Return on Capital Employed (ROCE)
- -0.41
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.17M
- Employee Count
- 20
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Kalaris Therapeutics is -1.02. Kalaris Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.02
- PS Ratio
- 0.00
- PB Ratio
- 0.94
- Price to FCF
- -1.05
- Price to Operating Cash Flow
- -1.05
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Kalaris Therapeutics had revenue of 0 and earned -43.44M in profits. Earnings per share was -2.85.
- Revenue
- 0
- Gross Profit
- -13.00K
- Operating Income
- -46.15M
- Pretax Income
- -43.44M
- Net Income
- -43.44M
- EBITDA
- -41.98M
- Earnings Per Share (EPS)
- -2.85
Cash Flow
In the last 12 months, operating cash flow was -43.17M and capital expenditures -200,000, giving a free cash flow of -43.37M billion.
- Operating Cash Flow
- -43.17M
- Free Cash Flow
- -43.37M
- Free Cash Flow per Share
- -1.78
Dividends & Yields
Kalaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -79.56%
- Earnings Yield
- -79.60%
Stock Price Statistics
- Beta
- 1.12
- 52-Week Price Change
- -48.84%
- 50-Day Moving Average
- 2.75
- 200-Day Moving Average
- 5.14
- Relative Strength Index (RSI)
- 54.41
- Average Volume (3m)
- 69.97K
Important Dates
Kalaris Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Kalaris Therapeutics as a current ratio of 12.23, with Debt / Equity ratio of 1.84%
- Current Ratio
- 12.23
- Quick Ratio
- 12.23
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.30
- Interest Coverage Ratio
- -31.98
Taxes
In the past 12 months, Kalaris Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Kalaris Therapeutics EV to EBITDA ratio is -1.21, with an EV/FCF ratio of -1.26.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.21
- EV to Free Cash Flow
- -1.26
- EV to Operating Cash Flow
- -1.26
Balance Sheet
Kalaris Therapeutics has $93.54M in cash and marketable securities with $1.40M in debt, giving a net cash position of $92.14M billion.
- Cash & Marketable Securities
- $93.54M
- Total Debt
- $1.40M
- Net Cash
- $92.14M
- Net Cash Per Share
- $3.87
- Tangible Book Value Per Share
- $2.42
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Kalaris Therapeutics is $14.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $14.00
- Price Target Upside
- 478.51% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 73.44%
Scores
- Smart Score
- 5
- AI Score
- 45
